newsfilter
← Latest News
GlobeNewswire·

eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) (the "Company"), a leader in the development of selective translation regulator inhibitors